Neurocrine Biosciences, Inc. announced its financial results for the first quarter ended March 31, 2025, and reaffirmed its 2025 financial guidance. INGREZZA net product sales for Q1 2025 were $545.2 million, an increase from $506.0 million in Q1 2024. CRENESSITY, launched in December 2024, contributed $14.5 million in net product sales with 413 total patient enrollment start forms.
Total revenues for the quarter reached $572.6 million, compared to $515.3 million in Q1 2024. The company reported GAAP net income of $7.9 million, or $0.08 diluted earnings per share. As of March 31, 2025, Neurocrine held $1,758.8 million in cash, cash equivalents, and marketable securities.
Neurocrine reaffirmed its 2025 INGREZZA net product sales guidance of $2.5 billion to $2.6 billion. The company also highlighted a record number of new patient starts for INGREZZA and ongoing Phase 3 registrational programs for osavampator in MDD and NBI-'568 in schizophrenia, positioning for future growth and innovation in neuroscience.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.